In earlier laboratory experiments, researchers had observed that mRNA vaccines improve the effectiveness of cancer drugs such as Merck's Keytruda, known as immune checkpoint inhibitors, in part by inducing the cancer cells to increase production of the same PD-L1 protein that the drugs are designed to recognize and block.